Dianthus Therapeutics Inc (NASDAQ:DNTH)’s traded shares stood at 1.52 million during the latest session, with the company’s beta value hitting 1.78. At the last check today, the stock’s price was $26.60, to imply an increase of 0.95% or $0.25 in intraday trading. The DNTH share’s 52-week high remains $33.77, putting it -26.95% down since that peak but still an impressive 75.26% since price per share fell to its 52-week low of $6.58. The company has a valuation of $787.29M, with an average of 0.22 million shares in intraday trading volume over the past 10 days and average of 201.59K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Dianthus Therapeutics Inc (DNTH), translating to a mean rating of 1.18. Of 6 analyst(s) looking at the stock, 0 analyst(s) give DNTH a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 6 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.82.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Dianthus Therapeutics Inc (NASDAQ:DNTH) trade information
After registering a 0.95% upside in the latest session, Dianthus Therapeutics Inc (DNTH) has traded red over the past five days. The 5-day price performance for the stock is -11.04%, and -4.90% over 30 days. With these gigs, the year-to-date price performance is 155.77%. Short interest in Dianthus Therapeutics Inc (NASDAQ:DNTH) saw shorts transact 5.1 million shares and set a 23.02 days time to cover.
The extremes give us $51 and $52 for target low and target high price respectively. As such, DNTH has been trading -95.49% off suggested target high and -91.73% from its likely low.
Dianthus Therapeutics Inc (DNTH) estimates and forecasts
Looking at statistics comparing Dianthus Therapeutics Inc share performance against respective industry, we note that the company has outperformed competitors. Dianthus Therapeutics Inc (DNTH) shares are 1.34% up over the last 6 months, with its year-to-date growth rate higher than industry average at 69.11% against 16.90%. Revenue is forecast to shrink -16.20% this quarter before falling -56.17% for the next one. The rating firms project that company’s revenue will grow 107.23% compared to the previous financial year.
Revenue forecast for the current quarter as set by 9 analysts is 844.11k. Meanwhile, for the current quarter, a total of 6 analyst(s) estimate revenue growth to 762k.Earnings reports from the last fiscal year show that sales brought in 457k and 874k respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 84.71% before dropping -12.81% in the following quarter.
DNTH Dividends
Dianthus Therapeutics Inc has its next earnings report out on 2025-Mar-19. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Dianthus Therapeutics Inc (NASDAQ:DNTH)’s Major holders
Dianthus Therapeutics Inc insiders hold 8.76% of total outstanding shares, with institutional holders owning 100.65% of the shares at 110.31% float percentage. In total, 100.65% institutions holds shares in the company.
